Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:51 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,468 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults

NCT04296279
View directory record Official record
Conditions
Vaccine Reaction
Interventions
FMP014, ALFQ
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Nov 2, 2026, 5:51 AM EST
Terminated Phase 3 Interventional Results available

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990
View directory record Official record
Conditions
Infectious Pneumonia, Severe COVID-19
Interventions
Reparixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54

NCT03882528
View directory record Official record
Conditions
Malaria,Falciparum
Interventions
Plasmodium falciparum malaria parasite
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Nov 2, 2026, 5:51 AM EST
Completed Not applicable Interventional

Effect of CAUTI Prevention Alert - A Randomized Control Trial

NCT02054065
View directory record Official record
Conditions
Infection Due to Indwelling Urinary Catheter
Interventions
CAUTI Decision Support
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 3 Interventional Results available

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

NCT03269994
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases
Interventions
Cefoxitin, Piperacillin-tazobactam
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
29
States / cities
Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 1 Interventional

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Nov 2, 2026, 5:51 AM EST
Terminated Not applicable Interventional

Acupuncture and Post-Surgical Wound Healing

NCT00260494
View directory record Official record
Conditions
Postoperative Complications, Surgical Wound Infection, Surgical Wound Dehiscence
Interventions
acupuncture, sham acupuncture
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

NCT00566345
View directory record Official record
Conditions
Influenza
Interventions
Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
Biological · Other
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
3,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Nov 2, 2026, 5:51 AM EST
Terminated Phase 2 Interventional

Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

NCT04117477
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Xylitol, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 2, 2026, 5:51 AM EST
Withdrawn Phase 4 Interventional

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

NCT02719392
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
N-acetylcysteine, Minocycline, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741
View directory record Official record
Conditions
DENV-3 Controlled Human Infection Model
Interventions
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 1 Interventional

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

NCT00000812
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
6
States / cities
Aurora, Colorado • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 2, 2026, 5:51 AM EST
Not listed Not applicable Interventional

Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients

NCT04581161
View directory record Official record
Conditions
Acute Respiratory Failure, Covid19
Interventions
Life2000® Ventilator
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Nov 2, 2026, 5:51 AM EST
Terminated Phase 4 Interventional Results available

Randomized Trial Comparing Irrisept to Saline Irrigation for Infection Prevention

NCT05402995
View directory record Official record
Conditions
Gustilo-Anderson Type III Open Tibia Fracture
Interventions
Irrisept (Irrigation Solution), Saline
Drug
Lead sponsor
Brett D. Crist
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Nov 2, 2026, 5:51 AM EST
Completed Not applicable Interventional

Video Discharge Instructions (VDI) as Adjuncts to Written Discharge Instructions in the Emergency Department

NCT02882256
View directory record Official record
Conditions
Urinary Tract Infection, Head Injury, Laceration
Interventions
Video discharge instructions
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Nov 2, 2026, 5:51 AM EST
Active, not recruiting Phase 2 Interventional Results available

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT04060277
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 2, 2026, 5:51 AM EST
Completed Not applicable Interventional

BFR Therapy for Post-Op Rehab of ACL Reconstruction With Quadriceps Tendon Autograft

NCT04519801
View directory record Official record
Conditions
ACL Injury
Interventions
Blood Flow Restriction (BFR) therapy, Standard REHAB
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
15 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 2, 2026, 5:51 AM EST
Terminated Not applicable Interventional Results available

Incisional Negative Pressure Wound Therapy

NCT01759381
View directory record Official record
Conditions
Spinal Deformity
Interventions
Negative pressure wound therapy (NPWT)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Nov 2, 2026, 5:51 AM EST
Recruiting Phase 3 Interventional

Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures

NCT06337292
View directory record Official record
Conditions
Fracture of Tibia, Wound Heal, Infected Wound, Wound Complication, Wound Dehiscence
Interventions
Incisional Negative Pressure Wound Therapy (NPWT)
Device
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 2, 2026, 5:51 AM EST
Completed Not applicable Interventional

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

NCT00490412
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT00851890
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Nov 2, 2026, 5:51 AM EST
Completed Phase 3 Interventional

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

NCT00404885
View directory record Official record
Conditions
Uveitis, Anterior, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Nov 2, 2026, 5:51 AM EST